Cannabis smoking is highly prevalent among patients with psychotic disorders. Its use has been found to be related to clinical characteristics and the prognosis of the disorder. Recent evidence indicates a protective effect of cannabis on weight gain and related metabolic alterations. However, there are no previous studies on the long-term longitudinal effects of cannabis on first-episode drug-naïve patients, which would thereby avoid the confounding effects of chronicity and previous treatment exposure. We aimed to explore the effect of cannabis smoking on weight and lipid/glycaemic metabolic measures in a sample of first-episode non-affective psychosis patients.
Method:
Anthropometric measurements and glycaemic and lipid parameters were obtained at baseline and three years after initiation of treatment. Patients self-reported their cannabis use at both time points. To explore the longitudinal effect of cannabis, patients were divided into three groups: continuers, discontinuers and non-users.
Results:
Cannabis users at baseline presented a lower weight (F=14.85, p<0.001), body mass index (F=13.14, p<0.001), total cholesterol (F=4.85, p=0.028) and low-density lipoprotein-cholesterol (F=6.26, p=0.013) compared to non-users. These differences were also observed after three years: weight (F=8.07, p=0.005), body mass index (F=4.66, p=0.032) and low-density lipoprotein-cholesterol (F=3.91, p=0.049). Moreover, those patients discontinuing cannabis use presented a higher increase in weight (F=2.98, p=0.052), body mass index (F=2.73, p=0.067) and triglyceride-high-density lipoprotein ratio (F=2.72, p=0.067) than the ‘non-users’ and ‘continuers’.
Conclusions:
The study suggests that cannabis use may produce a protective effect against weight gain and related metabolic alterations in psychosis. However, these results need to be replicated in a larger sample size.
AlbertiKGMMEckelRHGrundySMet al. (2009) Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation120: 1640–1645.
2.
AlshaarawyOAnthonyJC (2015) Cannabis smoking and diabetes mellitus: Results from meta-analysis with eight independent replication samples. Epidemiology26: 597–600.
3.
AlshaarawyOElbazHA (2016) Cannabis use and blood pressure levels: United States National Health and Nutrition Examination Survey, 2005–2012. J Hypertens34: 1507–1512.
4.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Press Inc.
5.
AndradeC (2016) Cardiometabolic risks in schizophrenia and directions for intervention, 1: Magnitude and moderators of the problem. J Clin Psychiatry77: e844–e847.
6.
ArguetaDADiPatrizioNV (2017) Peripheral endocannabinoid signaling controls hyperphagia in western diet-induced obesity. Physiol Behav171: 32–39.
7.
BellocchioLLafenêtrePCannichAet al. (2010) Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci13: 281–283.
8.
BruinsJPijnenborgMGBartels-VelthuisAAet al. (2016) Cannabis use in people with severe mental illness: The association with physical and mental health–a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study. J Psychopharmacol30: 354–362.
9.
Crespo-FacorroBPérez-IglesiasRMataIet al. (2012) Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: Results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl)219: 225–233.
10.
CorrellCURobinsonDGSchoolerNRet al. (2014) Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP study. JAMA Psychiatry71: 1350–1363.
11.
DanielssonAKLundinAYaregalAet al. (2016) Cannabis use as risk or protection for type 2 diabetes: A longitudinal study of 18 000 Swedish men and women. J Diabetes Res2016: 6278709.
12.
de HertMCohenDBobesJet al. (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry10: 52–77.
13.
de SilvaVADayabandaraMWijesundaraHet al. (2015) Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. J Psychopharmacol29: 1255–1261.
14.
de SilvaVASuraweeraCRatnatungaSSet al. (2016) Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry16: 341.
15.
EllingrodVLTaylorSFBrookRDet al. (2011) Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res130: 20–26.
16.
FoleyDLMorleyKI (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry68: 609–616.
17.
FriedewaldWTLevyRIFredricksonDS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem18: 499–502.
18.
Gómez-RevueltaMPelayo-TeránJMJuncal-RuizMet al. (2018) Long-term antipsychotic effectiveness in First Episode of Psychosis: A 3-year follow-up randomized clinical trial comparing aripiprazole, quetiapine and ziprasidone. Int J Neuropsychopharmacol21: 1090–1101.
19.
GreenBYoungRKavanaghD (2005) Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry187: 306–313.
20.
HarrisonERHaagaJRichardsT (1993) Self-reported drug use data: What do they reveal?Am J Drug Alcohol Abuse19: 423–441.
21.
HayatbakhshMRO’CallaghanMJMamunAAet al. (2010) Cannabis use and obesity and young adults. Am J Drug Alcohol Abuse36: 350–356.
22.
HicklingLMOrtiz-García de la FozVAyesa-ArriolaRet al. (2017) The effects of tobacco smoking on age of onset of psychosis and psychotic symptoms in a first-episode psychosis population. Addiction112: 526–532.
23.
HjorthøjCStürupAEMcGrathJJet al. (2017) Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. Lancet Psychiatry4: 295–301.
24.
HsiaoWCShiaKSWangYTet al. (2015) A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Diabetes Obes Metab17: 495–504.
25.
JensenKGCorrellCURudåDet al. (2017) Pretreatment cardiometabolic status in youth with early-onset psychosis: Baseline results from the TEA trial. J Clin Psychiatry78: e1035–e1046.
26.
JinLZRanganAMehlsenJet al. (2017) Association between use of cannabis in adolescence and weight change into midlife. PLOS ONE12: e0168897.
27.
Jockers-ScherublMCWolfTRadzeiNet al. (2007) Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry31: 1054–1063.
28.
LabbéSMCaronALanfrayDet al. (2015) Hypothalamic control of brown adipose tissue thermogenesis. Front Syst Neurosci9: 150.
29.
LaprairieRBBagherAMKellyMEet al. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol172: 4790–4805.
30.
Le StratYLe FollB (2011) Obesity and cannabis use: Results from 2 representative national surveys. Am J Epidemiol174: 929–933.
ManuPDimaLShulmanMet al. (2015) Weight gain and obesity in schizophrenia: Epidemiology, pathobiology, and management. Acta Psychiatrica Scandinavica132: 97–108.
33.
MatthewsDRHoskerJPRudenskiASet al. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia28: 412–419.
34.
McLaughlinTReavenGAbbasiFet al. (2005) Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?Am J Cardiol96: 399–404.
NaslundJAWhitemanKLMcHugoGJet al. (2017) Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis. Gen Hosp Psychiatry47: 83–102.
37.
NguetaGBélangerRELaouan-SidiEAet al. (2015) Cannabis use in relation to obesity and insulin resistance in the Inuit population. Obesity23: 290–295.
38.
Pelayo-TeránJMDiazFJPérez-IglesiasRet al. (2014) Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med44: 37–50.
39.
Pelayo-TeránJMPérez-IglesiasRRamírez-BonillaMet al. (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: Insights from the clinical programme on early phases of psychosis. Early Interv Psychiatry2: 178–187.
40.
PennerEABuettnerHMittlemanMA (2013) The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med126: 583–589.
41.
PillingerTBeckKGobjilaCet al. (2017) Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry74: 261–269.
42.
PopeHGJrGruberAJHudsonJIet al. (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry58: 909–915.
43.
RadoJvon Ammon CavanaughS (2016) A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. J Clin Psychopharmacol36: 163–168.
44.
RajavashisthTBShaheenMNorrisKCet al. (2012) Decreased prevalence of diabetes in marijuana users: Cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. BMJ Open2: e000494.
45.
RossJMGrazianoPPacheco-ColónIet al. (2016) Decision-making does not moderate the association between cannabis use and body mass index among adolescent cannabis users. J Int Neuropsychol Soc22: 944–949.
46.
Ruiz de AzuaIManciniGSrivastavaRKet al. (2017) Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages. J Clin Invest127: 4148–4162; pii: 83626.
47.
Setién-SueroENeergaardKRamírez-BonillaMet al. (2017) Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences. PLOS ONE12: e0183613.
48.
SimonVCotaD (2017) Mechanisms in endocrinology: Endocannabinoids and metabolism: Past, present and future. Eur J Endocrinol176: R309–R324.
49.
StahlSMMignonLMeyerJM (2009) Which comes first: Atypical antipsychotic treatment or cardiometabolic risk?Acta Psychiatr Scand119: 171–179.
50.
TeixeiraDPestanaDFariaAet al. (2010) Modulation of adipocyte biology by δ(9)-tetrahydrocannabinol. Obesity18: 2077–2085.
51.
van der MeerFJVelthorstE; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2015) Course of cannabis use and clinical outcome in patients with non-affective psychosis: A 3-year follow-up study. Psychol Med45: 1977–1988.
52.
Vázquez-BourgonJPérez-IglesiasROrtiz-García de la FozVet al. (2018) Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: A pragmatic clinical trial in drug-naïve patients with a first-episode of psychosis. Psychopharmacology235: 245–255.
53.
VreelandB (2007) Treatment decisions in major mental illness: Weighing the outcomes. J Clin Psychiatry68: 5–11.
54.
WaterreusABadcockJCDi PrinzioPet al. (2017) The impact of current cannabis use on general cognitive function in people with psychotic illness. Schizophr Res190: 164–171; pii: S0920–9964(17)30177–9.
55.
WaterreusADi PrinzioPWattsGFet al. (2016) Metabolic syndrome in people with a psychotic illness: Is cannabis protective?Psychol Med46: 1651–1662.
56.
ZhaiDLangYFengYet al. (2017) Early onset of cardiometabolic risk factor profiles in drug naïve adolescents and young adults with first-episode schizophrenia. Schizophr Res190: 60–62.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
